JP2018530587A - ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法 - Google Patents

ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法 Download PDF

Info

Publication number
JP2018530587A
JP2018530587A JP2018519312A JP2018519312A JP2018530587A JP 2018530587 A JP2018530587 A JP 2018530587A JP 2018519312 A JP2018519312 A JP 2018519312A JP 2018519312 A JP2018519312 A JP 2018519312A JP 2018530587 A JP2018530587 A JP 2018530587A
Authority
JP
Japan
Prior art keywords
alkyl
halo
compound according
optionally substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018519312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530587A5 (enExample
Inventor
ブトラ、ガボール
スタントン、マシュー
スティール、トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of JP2018530587A publication Critical patent/JP2018530587A/ja
Publication of JP2018530587A5 publication Critical patent/JP2018530587A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018519312A 2015-10-16 2016-10-17 ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法 Pending JP2018530587A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242881P 2015-10-16 2015-10-16
US62/242,881 2015-10-16
PCT/US2016/057405 WO2017066793A1 (en) 2015-10-16 2016-10-17 Mrna cap analogs and methods of mrna capping

Publications (2)

Publication Number Publication Date
JP2018530587A true JP2018530587A (ja) 2018-10-18
JP2018530587A5 JP2018530587A5 (enExample) 2019-11-28

Family

ID=57219027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519312A Pending JP2018530587A (ja) 2015-10-16 2016-10-17 ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法

Country Status (6)

Country Link
US (1) US20190225644A1 (enExample)
EP (1) EP3362460A1 (enExample)
JP (1) JP2018530587A (enExample)
AU (1) AU2016340183A1 (enExample)
CA (1) CA3001014A1 (enExample)
WO (1) WO2017066793A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023540562A (ja) * 2020-09-04 2023-09-25 ヴァーヴ・セラピューティクス，インコーポレーテッド Ｒｎａをキャッピングするための組成物および方法

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066781A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
EP4494652A3 (en) 2017-07-04 2025-05-14 CureVac SE Cancer rna-vaccine
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
US11692002B2 (en) 2017-11-08 2023-07-04 CureVac SE RNA sequence adaptation
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
US11897911B2 (en) * 2018-03-07 2024-02-13 Sanofi Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same
BR112020026125A8 (pt) * 2018-03-15 2022-10-18 Biontech Rna Pharmaceuticals Gmbh Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
US20210361761A1 (en) 2018-04-05 2021-11-25 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
KR20210003811A (ko) 2018-04-17 2021-01-14 큐어백 아게 백신 접종을 위한 신규 rsv rna 분자 및 조성물
CN108484690B (zh) * 2018-05-16 2021-04-30 新乡拓新药业股份有限公司 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
EP3846822A4 (en) * 2018-09-04 2022-07-06 The Board Of Regents Of The University Of Texas System COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS
BR112021009422A2 (pt) 2018-12-21 2021-10-26 Curevac Ag Rna para vacinas contra malária
WO2020127959A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
CA3125511A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
BR112021019465A8 (pt) 2019-04-02 2022-06-07 Aligos Therapeutics Inc Compostos que têm como alvo prmt5
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
CN112390838A (zh) * 2019-08-14 2021-02-23 斯微(上海)生物科技有限公司 一种改性核苷及其合成方法
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
CA3146835A1 (en) * 2019-09-05 2021-03-11 Mitorainbow Therapeutics, Inc. Treating mitochondrial dna depletion disorders
CA3162019A1 (en) 2019-12-20 2021-06-24 Gemma NAVARRO Lipid nanoparticles for delivery of nucleic acids
DE112021000012C9 (de) 2020-02-04 2025-02-06 CureVac SE Coronavirus-Vakzine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
CN118490818A (zh) * 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
AU2021279312A1 (en) 2020-05-29 2022-12-15 CureVac SE Nucleic acid based combination vaccines
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
JP2024502210A (ja) 2020-12-22 2024-01-17 キュアバック エスイー ＳＡＲＳ－ＣｏＶ－２バリアントに対するＲＮＡワクチン
EP4087938A2 (en) 2021-01-27 2022-11-16 CureVac AG Method of reducing the immunostimulatory properties of in vitro transcribed rna
CN117377491A (zh) 2021-03-26 2024-01-09 葛兰素史克生物有限公司 免疫原性组合物
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
US11649260B2 (en) 2021-06-18 2023-05-16 Hongene Biotech Corporation Functionalized N-acetylgalactosamine nucleosides
US20250002524A1 (en) * 2021-07-30 2025-01-02 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
WO2023006999A2 (en) 2021-07-30 2023-02-02 CureVac SE Mrnas for treatment or prophylaxis of liver diseases
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4396193A4 (en) 2021-08-30 2025-07-02 Hongene Biotech Corp FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
US20240398940A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
JP2024546585A (ja) 2021-12-15 2024-12-26 ホンジーン バイオテック コーポレイション 官能基化ｎ－アセチルガラクトサミンアナログ
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
AU2023227443A1 (en) 2022-03-01 2024-10-10 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
US20250228975A1 (en) 2022-03-21 2025-07-17 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
CN114685588B (zh) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 一种含开环核苷结构的起始加帽寡核苷酸引物
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CN115057903B (zh) * 2022-06-22 2024-03-29 江苏申基生物科技有限公司 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用
WO2023246860A1 (zh) * 2022-06-22 2023-12-28 江苏申基生物科技有限公司 一种起始加帽寡核苷酸引物及其制备方法和应用
CN114853836B (zh) * 2022-06-24 2024-05-14 江苏申基生物科技有限公司 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用
CN115109110B (zh) * 2022-06-22 2024-07-12 江苏申基生物科技有限公司 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
CN115947759A (zh) * 2022-12-13 2023-04-11 安徽大学 一种治疗新冠药物瑞德西韦的制备方法
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024235451A1 (en) 2023-05-16 2024-11-21 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
AU2024278682A1 (en) 2023-05-26 2025-11-27 CureVac SE Cancer antigens
WO2024260570A1 (en) 2023-06-23 2024-12-26 CureVac SE Nucleic acid encoded antibodies
WO2025005647A1 (ko) * 2023-06-26 2025-01-02 전북대학교산학협력단 새로운 변형 트리뉴클레오티드 캡핑 유도체와 캡핑 유도체가 도입된 mRNA
US20250027087A1 (en) 2023-07-21 2025-01-23 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
CN116987137B (zh) * 2023-09-26 2024-01-02 江苏申基生物科技有限公司 一种加帽化合物及其在mRNA加帽中的应用
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025141025A2 (en) * 2023-12-26 2025-07-03 Eleven Therapeutics Ltd Novel capping strategies for mrna 5'cap
WO2025181704A2 (en) 2024-02-27 2025-09-04 Crispr Therapeutics Ag Rt editing compositions and methods
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539948A (ja) * 2013-11-27 2016-12-22 グローバラコーン リミテッド 組成物

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
WO1999024595A1 (en) 1997-11-12 1999-05-20 The Brigham And Women's Hospital, Inc. The translation enhancer element of the human amyloid precursor protein gene
US6429301B1 (en) * 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
EP1073730A1 (en) * 1998-04-17 2001-02-07 Whitehead For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
EP1274838A1 (en) 2000-01-28 2003-01-15 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying the same
US8273866B2 (en) * 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
CA2457959C (en) * 2001-06-05 2014-10-28 Curevac Gmbh Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
TR201909609T4 (tr) * 2005-08-23 2019-07-22 Univ Pennsylvania Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
EP2479254A1 (en) 2005-08-24 2012-07-25 The Scripps Research Institute Translation enhancer-element dependent vector systems
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
JP2009544754A (ja) * 2006-07-28 2009-12-17 アプライド バイオシステムズ， エルエルシー ジヌクレオチドｍｒｎａキャップアナログ
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
SG10201408162PA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
CN101932707B (zh) 2008-01-31 2013-08-21 库瑞瓦格有限责任公司 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物
KR101620394B1 (ko) * 2008-04-03 2016-05-12 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
AU2010218388B2 (en) * 2009-02-24 2015-03-26 The Scripps Research Institute Reengineering mRNA primary structure for enhanced protein production
EP2281579A1 (en) * 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
AU2010326132B9 (en) * 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
US8802438B2 (en) * 2010-04-16 2014-08-12 Children's Medical Center Corporation Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US20130230884A1 (en) 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
US8968746B2 (en) 2010-07-30 2015-03-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013059475A1 (en) * 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US9890391B2 (en) 2012-03-27 2018-02-13 Curevac Ag RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
ES2660129T3 (es) 2012-03-27 2018-03-20 Curevac Ag Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
CA2859452C (en) 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
US20150306249A1 (en) 2012-05-25 2015-10-29 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
CA2892529C (en) * 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
SG10201710473VA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
WO2014152673A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
WO2015002667A1 (en) 2013-07-01 2015-01-08 Myq, Inc. A location regulated point-of-sale system and enhancements
SG11201600987TA (en) 2013-08-16 2016-03-30 Rana Therapeutics Inc Compositions and methods for modulating rna
SG10201801433XA (en) 2013-08-21 2018-04-27 Curevac Ag Composition and vaccine for treating prostate cancer
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
UA120595C2 (uk) 2013-08-21 2020-01-10 Куревак Аг Композиція та вакцина для лікування недрібноклітинного раку легень
AU2014310933B2 (en) 2013-08-21 2020-05-14 CureVac SE Method for increasing expression of RNA-encoded proteins
CN105517569A (zh) 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
SG10201903381TA (en) 2013-12-30 2019-05-30 Curevac Ag Artificial nucleic acid molecules
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
WO2017066781A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539948A (ja) * 2013-11-27 2016-12-22 グローバラコーン リミテッド 組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOCHEMISTRY, vol. 38, JPN6020046262, 1999, pages 8538 - 8547, ISSN: 0004543924 *
J.AM.CHEM., vol. 131, JPN6020046263, 2009, pages 6364 - 6365, ISSN: 0004543927 *
J.ORG.CHEM., vol. 64, JPN6020046261, 16 July 1999 (1999-07-16), pages 5836 - 5840, ISSN: 0004543923 *
JOSEPHIN MARIE HOLSTEIN, CHEMICAL COMMUNICATIONS, vol. vol.50(34), JPN5018007095, 2014, pages 4478 - 4481, ISSN: 0004543925 *
KOWALSKA JOANNA, NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. vol.24(5-7), JPN5018007093, 2005, US, pages 595 - 600, ISSN: 0004543928 *
MALWINA STRENKOWSKA, NEW JOURNAL OF CHEMISTRY, vol. vol.34(5), JPN5018007094, 2010, GB, pages 993 - 1007, ISSN: 0004543926 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023540562A (ja) * 2020-09-04 2023-09-25 ヴァーヴ・セラピューティクス，インコーポレーテッド Ｒｎａをキャッピングするための組成物および方法

Also Published As

Publication number Publication date
CA3001014A1 (en) 2017-04-20
WO2017066793A1 (en) 2017-04-20
AU2016340183A1 (en) 2018-04-19
US20190225644A1 (en) 2019-07-25
EP3362460A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
US10428106B2 (en) Phosphate replacement mRNA cap analogs
JP2018530587A (ja) ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
US11866754B2 (en) Trinucleotide mRNA cap analogs
JP7019639B2 (ja) 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
WO2017066789A1 (en) Mrna cap analogs with modified sugar
WO2017066782A1 (en) Hydrophobic mrna cap analogs
WO2017066791A1 (en) Sugar substituted mrna cap analogs
JP2025061366A (ja) 安定化尾部領域を含むポリヌクレオチド
WO2015196118A1 (en) Alternative nucleic acid molecules and uses thereof
CN106170553A (zh) 修饰的核酸分子及其用途
US20200362382A1 (en) Methods of preparing modified rna
HK40032374A (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
HK40032374B (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210706